Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1575 - The efficacy and safety of sorafenib in patients with renal insufficiency of advanced renal cell carcinoma: real- world data of sorafenib in Japan.

Date

10 Sep 2017

Session

Poster display session

Presenters

Katsunori Tatsugami

Citation

Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371

Authors

K. Tatsugami1, M. Oya2, K. Kabu3, H. Akaza4

Author affiliations

  • 1 Urology, Graduate School of Medical Science, Kyushu University, 812-8582 - Fukuoka/JP
  • 2 Urology, Keio University School of Medicine, 160-8582 - Tokyo/JP
  • 3 Medical Affairs Oncology And Hematology, Bayer Yakuhin, Ltd., 100-8625 - Tokyo/JP
  • 4 Strategic Investigation On Comprehensive Cancer Network, The University of Tokyo, 153-8904 - Tokyo/JP
More

Resources

Abstract 1575

Background

Multiple treatment options are available for patients with advanced renal cell carcinoma (aRCC). However, the safety/efficacy data of these agents in patients with renal insufficiency are limited. To assess the safety/efficacy of sorafenib in aRCC patients with renal insufficiency, we analyzed the real-world data of a nationwide prospective post-marketing surveillance applying propensity score-matched cohorts.

Methods

A total of 3,255 patients with aRCC were enrolled, and 1,226 patients of whom were selected by propensity score matching for estimated glomerular filtration rate (eGFR)

Results

The median PFS in eGFR

Conclusions

Sorafenib has little impact on the renal function in almost all patients with renal insufficiency and provide the fine therapeutic effects for these aRCC patients.

Clinical trial identification

Legal entity responsible for the study

Bayer Yakuhin Ltd.

Funding

Bayer Yakuhin Ltd.

Disclosure

K. Tatsugami, M. Oya, H. Akaza: Speaker\'s Bureau: Bayer Yakuhin Ltd., Pfizer, Novartis, Ono Pharmaceutical co., Ltd., and Bristol-Myers. K. Kabu: An employee of Bayer Yakuhin Ltd.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.